KRAS and non-small cell lung carcinoma: Furthermore, we have shown significant intracranial activity of adagrasib in BM mouse models of KRAS-G12C NSCLC, and preliminary but encouraging anti-tumor effects with effective cerebrospinal fluid (CSF) penetration in patients with KRAS-G12C BM [6].